Sign in to continue:

Friday, March 6th, 2026

Xiamen Yan Palace Bird’s Nest Industry Announces Board Meeting to Approve 2025 Annual Results and Dividend Recommendation 1

Xiamen Yan Palace Bird’s Nest Industry Co., Ltd. Announces Board Meeting for 2025 Annual Results

Xiamen Yan Palace Bird’s Nest Industry Co., Ltd. Announces Board Meeting for 2025 Annual Results

Key Highlights for Investors

  • Scheduled Board Meeting: The board of directors of Xiamen Yan Palace Bird’s Nest Industry Co., Ltd. (“the Company”) has announced that a board meeting will be held on Tuesday, March 17, 2026.
  • Purpose of the Meeting: The primary agenda of this board meeting is to consider and approve the annual results for the financial year ended December 31, 2025.
  • Dividend Consideration: The board will also discuss the recommendation of a final dividend for shareholders. This is a potentially price-sensitive event as the announcement or size of a dividend can significantly affect share value.
  • Other Business: The board may also transact other business matters during this meeting.

Implications for Shareholders

The announcement of a board meeting to approve annual results and consider a final dividend is a significant event for shareholders. The declaration of a dividend, or any changes to dividend policies, can directly influence share price. Investors should note the following:

  • Potential Dividend Announcement: Shareholders should pay close attention to any final dividend that may be recommended, as this will directly impact their returns and could lead to increased trading activity.
  • Financial Performance Disclosure: The publication of the annual results will provide insights into the Group’s operating performance, profitability, and future prospects, which are key drivers of share price movement.
  • Other Decisions: Any additional business or strategic decisions made during the meeting could also affect the Group’s outlook and valuation.

Board Composition

As of the date of this announcement, the Company’s board comprises:

  • Executive Directors: Mr. HUANG Jian (Chairman and Executive Director), Mr. ZHENG Wenbin, Mr. LI Youquan, and Ms. HUANG Danyan
  • Non-Executive Directors: Mr. LIU Zhen and Mr. WANG Yalong
  • Independent Non-Executive Directors: Mr. XIAO Wei, Mr. CHEN Aihua, and Mr. LAM Yiu Por

What Should Investors Watch For?

Shareholders and potential investors should mark March 17, 2026 on their calendars, as the meeting outcomes—particularly the financial results and any dividend announcement—are likely to be material and could trigger share price movements, depending on whether the results meet, exceed, or fall short of market expectations.

Disclaimer

This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own research or consult professional advisors before making any investment decisions. The information is based on the latest company announcement as of March 5, 2026.


View YAN PALACE Historical chart here



BlackRock Inc. Discloses Sale of ENN Energy Holdings Shares Amid Privatisation Scheme (March 2026)

BlackRock Discloses Sale of ENN Energy Holdings Ltd Shares Amid Privatisation Scheme BlackRock Discloses Sale of ENN Energy Holdings Ltd Shares Amid Privatisation Scheme Key Points from the Disclosure Date of Transaction: 27 February...

Clarity Medical Group Holding Limited Announces Poll Results of Extraordinary General Meeting Held on 27 February 2026

Clarity Medical Group Holding Limited: Key Highlights from EGM Held on 27 February 2026 Clarity Medical Group Holding Limited: Poll Results and Key Takeaways from Extraordinary General Meeting Date: 27 February 2026 Stock Code:...

Sihuan Pharmaceutical’s Bireociclib (Xuanyuening) Receives NMPA Approval for First-Line HR+/HER2- Advanced Breast Cancer Treatment in China

Sihuan Pharmaceutical: Key Milestone in Breast Cancer Drug Approval Sihuan Pharmaceutical Achieves Landmark Drug Approval for Advanced Breast Cancer Treatment Key Highlights Marketing Approval Granted for Xuanyuening (Bireociclib Tablets) Third Indication: The National Medical...

   Ad